Memorial Sloan Kettering Cancer Center’s Post

Patients undergoing breast cancer screening by routine mammogram in 2024 may learn that they have dense breasts. How do you help your patients understand this information in terms of their risk for developing breast cancer? Breast density is not a description of breast size or firmness but describes different normal tissues. Talk with your patients about breast density alongside integrated breast cancer risk assessment that considers multiple evidence-based factors. https://lnkd.in/gva63wGH #breastcancer #breastdensity #geneType #bcsm #knowyourrisk #meded

October is Breast Cancer Awareness Month, and Greenwich LifeSciences (Nasdaq: GLSI) is advancing the fight against breast cancer recurrence with GP2, an innovative immunotherapy designed to prevent its return after surgery. Breast cancer is influenced by genetics, like BRCA1 and BRCA2, as well as lifestyle factors. GLSI is tackling this complexity by developing GP2, a targeted treatment for patients at risk of recurrence, especially those for whom existing therapies may not be enough. Now in a Phase 3 trial, GP2 offers hope by targeting the HER2/neu protein, found in over 75% of breast cancers. This groundbreaking approach could provide a more personalized solution to prevent recurrence. Learn more about GLSI and read our disclosures 👉 https://glsiinfo.com/ #BreastCancerAwarenessMonth #Immunotherapy #PreventRecurrence #biotech #financialnews

March marks Colorectal Cancer Awareness Month. The American Society of Colon and Rectal Surgeons estimates 140,000 new cases of colorectal cancer in the United States in 2024. At Activ Surgical, we are working to make surgical treatment of colorectal cancer easier with our ActivSight™ advanced visualization platform. Check out this quote from Dr. Emily Huang on her experience using ActivSight in her colorectal procedures. #ColorectalCancerAwarenessMonth #ASCRS #CRC #ActivSight #advancedvisualization

In January 2021, Bill Hoffman discovered two small lumps on his neck. Diagnosed with melanoma, he underwent surgery and immunotherapy but his cancer continued to progress, spreading to his lymph nodes. When he ran out of options, Bill turned to Moffitt Cancer Center, where he learned about the tumor-infiltrating lymphocyte (TIL) therapy, lifileucel and became Moffitt’s first commercial TIL therapy patient. On March 26, 2024, Bill underwent a tumor harvest, before receiving the lifileucel infusion on May 16. He is now waiting to find out if the treatment has been successful. “TIL therapy is the most reliable option after traditional standard-of-care therapies have failed”, said the center’s Dr. Amod Sarnaik. More trials are being conducted to find ways to reduce the manufacturing time and create a better product with a higher success rate. Treatments like lifileucel offer hope for patients with aggressive cancers. Ensuring these therapies are approvable, accessible and affordable is essential to providing life-saving options to more patients in need. Thank you Moffitt Cancer Center for sharing Bill’s inspiring story. https://lnkd.in/eEZvvmj6 #ManufacturingBrighterFutures #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

This weekend was #BreastCancerResearchDay: Breast cancer research is focused on developing targeted therapies that meet you where you are in your diagnosis and treatment. Whether you've just been diagnosed, have residual disease after surgery, or are facing advanced or metastatic breast cancer, we have clinical trials and cutting-edge therapies available. CHC Breast Cancer Clinical Trials : https://buff.ly/4czzHsN Breast Cancer: https://buff.ly/48vpAo5

🔍 Sentinel Biopsy: A Modern Approach 🩺 📈Did you know that SPECT-CT has been a standard procedure for sentinel node lymphoscintigraphy for oral cancer since 2010? At the Oral Cancer Institute (OCI), our surgeons specialize in performing sentinel lymph node biopsies (SNLB). SNLB offers an alternative to selective neck dissection for oral cavity cancers. It allows for sampling of lymph nodes in the neck to check for cancerous spread. Compared to traditional neck dissection, SNLB is typically shorter and utilizes smaller incisions. Wondering if you're a candidate for SNLB? Don't hesitate to ask your OCI surgeon about this modern approach to lymph node evaluation or call us today to schedule your appointment. ☎️ 773-245-5253 To find out more, visit our website: https://lnkd.in/en92Rdrj  #SentinelBiopsy #OralCancer #LymphNodeEvaluation #InnovativeProcedure #Healthcare #MedicalAdvancements #OralCancerInstitute #ExpertCare #SNLB #TreatmentOptions

One of the significant milestones in the history of cancer care is the discovery of chemotherapy. In the early 20th century, researchers discovered that mustard gas, used as a chemical weapon during World War I, had profound effects on rapidly dividing cells, including cancer cells. This led to the development of the first chemotherapy drugs, which paved the way for modern cancer treatment. Today, chemotherapy remains a crucial component of cancer therapy, alongside surgery, radiation, and newer targeted therapies and immunotherapies. #FridayCancerFact

Focused ultrasound is a noninvasive, therapeutic technology with the potential to improve the quality of life and decrease the cost of care for patients with breast cancer. This novel technology focuses beams of ultrasound energy precisely and accurately on targets in the body without damaging surrounding normal tissue. Breast Tumors, Malignant - Focused Ultrasound Foundation https://lnkd.in/ePzRMaCR https://lnkd.in/ePzRMaCR

📣 Exciting news! 📑 After the publication of the results from our multi-year collaboration with the The French Kidney Cancer Research Network (UroCCR), we're excited to launch UroPredict: A Machine-Learning Model on Real-World Data for the Prediction of Kidney Cancer Recurrence (UroCCR-120)*. 💡Applying machine learning (ML) to real-world prospective data from patients undergoing surgery for localized or locally advanced Renal Cell Carcinoma (RCC) can provide accurate individual disease-free survival (DFS) prediction, outperforming traditional prognostic scores that present moderate predictive performance, leading to challenges in establishing follow-up recommendations after surgery and in selecting patients who could benefit from adjuvant therapy. ❗🔎 Learn more and try the RCC Recurrence Predictor using your own data: https://loom.ly/bdqqwyE #UroCCR #datadrivenmedicine #RCC #kidneycancer #oncology #AIinHealthcare